Kai Pharms Inc Drug Patent Portfolio
Kai Pharms Inc owns 1 orange book drug protected by 8 US patents Given below is the list of Kai Pharms Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10344765 | Stable liquid formulation of AMG 416 (etelcalcetide) | 27 Jun, 2034 | Active |
| US11162500 | Stable liquid formulation of AMG 416 (etelcalcetide) | 27 Jun, 2034 | Active |
| US11959486 | Stable liquid formulation of AMG 416 (etelcalcetide) | 27 Jun, 2034 | Active |
| US9820938 | Stable liquid formulation of AMG 416 (etelcalcetide) | 27 Jun, 2034 | Active |
| US8999932 | Therapeutic agents for reducing parathyroid hormone levels | 07 Feb, 2031 | Active |
| US8377880 | Therapeutic agents for reducing parathyroid hormone levels | 29 Jul, 2030 | Active |
| US9278995 | Therapeutic agents for reducing parathyroid hormone levels | 29 Jul, 2030 | Active |
| US9701712 | Therapeutic agents for reducing parathyroid hormone levels | 29 Jul, 2030 | Active |
Latest Legal Activities on Kai Pharms Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Kai Pharms Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 Aug, 2023 | US9278995 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Dec, 2022 | US10344765 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Sep, 2022 | US8999932 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 02 Nov, 2021 | US11162500 |
|
Recordation of Patent Grant Mailed
Critical
| 02 Nov, 2021 | US11162500 |
|
Email Notification
Critical
| 14 Oct, 2021 | US11162500 |
|
Issue Notification Mailed
Critical
| 13 Oct, 2021 | US11162500 |
|
Application Is Considered Ready for Issue
Critical
| 04 Oct, 2021 | US11162500 |
| Dispatch to FDC | 04 Oct, 2021 | US11162500 |
|
Issue Fee Payment Received
Critical
| 02 Aug, 2021 | US11162500 |
|
Issue Fee Payment Verified
Critical
| 02 Aug, 2021 | US11162500 |
|
Email Notification
Critical
| 19 Jul, 2021 | US11162500 |
|
Electronic Review
Critical
| 19 Jul, 2021 | US11162500 |
|
Mail Notice of Allowance
Critical
| 19 Jul, 2021 | US11162500 |
|
Notice of Allowance Data Verification Completed
Critical
| 14 Jul, 2021 | US11162500 |
Kai Pharms Inc's Family Patents
Kai Pharms Inc drugs have patent protection in a total of 43 countries. It's US patent count contributes only to 19.3% of its total global patent coverage. Click
below to unlock the full patent family tree.
Kai Pharms Inc Drug List
Given below is the complete list of Kai Pharms Inc's drugs and the patents protecting them.
1. Parsabiv
Parsabiv is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10344765 | Stable liquid formulation of AMG 416 (etelcalcetide) |
27 Jun, 2034
(9 years from now)
| Active |
| US11162500 | Stable liquid formulation of AMG 416 (etelcalcetide) |
27 Jun, 2034
(9 years from now)
| Active |
| US11959486 | Stable liquid formulation of AMG 416 (etelcalcetide) |
27 Jun, 2034
(9 years from now)
| Active |
| US9820938 | Stable liquid formulation of AMG 416 (etelcalcetide) |
27 Jun, 2034
(9 years from now)
| Active |
| US8999932 | Therapeutic agents for reducing parathyroid hormone levels |
07 Feb, 2031
(6 years from now)
| Active |
| US8377880 | Therapeutic agents for reducing parathyroid hormone levels |
29 Jul, 2030
(5 years from now)
| Active |
| US9278995 | Therapeutic agents for reducing parathyroid hormone levels |
29 Jul, 2030
(5 years from now)
| Active |
| US9701712 | Therapeutic agents for reducing parathyroid hormone levels |
29 Jul, 2030
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Parsabiv's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List